Skip to main content

Table 3 Prevalence of hereditary coagulation defects

From: Elevated risk of thrombophilia in agenesis of the vena cava as a factor for deep vein thrombosis

  Patients with AIVC in this paper (n = 41) Patients with AIVC in literature research (n = 124) Patients with NoAIVC (n = 168) P Value of AIVC in this paper and in literature (n = 165) vs. NoAIVC (n = 168)
Factor V Leiden (%) 11/41 (26.8%) 16/124 (12.9%) 8/168 (4.8%) 0.001
Prothrombin gene mutation (%) 1/41 (2.4%) 8/124 (6.5%) 2/168 (1.2%) 0.146
MTHFR gene mutation (%) 15/41 (36.6%) 6/124 (4.8%) 6/168 (3.6%) 0.005
Homocysteinemia (%) 15/41 (36.6%) 5/124 (4.0%) 5/168 (3.0%) <0.0001
Lupus anticoagulant (%) 2/41 (4.9%) 4/124 (3.2%) 1/168 (0.6%) 0.053
Two thrombophilic factors positive (%) 9/41 (22.0%) 7/124 (5.6%) 4/168 (2.4%) 0.075
Three and more thrombophilic factors positive (%) 8/41 (19.5%) 1/124 (0.8%) 3/168 (1.8%) 0.086
  1. AIVC inferior vena cava agenesia. NoAIVC iliofemoral DVT with involvement of inferior vena cava without AIVC.
  2. One case homozygous for factor-V-Leiden-gene-mutation. Two cases homozygous for MTHFR-gene-mutation.